Slow Release T3 Dosing and Troubleshooting: The Complete 2026 Research Guide

This guide is the practical dosing and troubleshooting companion to the SR-T3 methodology pillar, which covers the pharmacokinetic case for slow-release liothyronine, the compounding landscape, and the clinical context in depth. Where that guide answers "what is SR-T3 and why does it exist," this one answers "how do you actually use it, what goes wrong, and what does the research community do about it." The cluster scope is narrow and practical: starting dose, titration tempo, timing decisions, food interactions, missed-dose protocol, and the structured troubleshooting framework that the bioenergetic research community has converged on for handling SR-T3 non-response and side-effect management.

Research framing. This article reviews slow release T3 dosing conventions and troubleshooting patterns discussed in research and bioenergetic-framework settings. It is not medical advice, and the dose figures cited are research-community reference points, not prescriptions. T3 products on this site are sold as research reference standards and are not approved for human consumption. See our research-use-only disclaimer for full terms.

Research Grade · Discreet Worldwide Shipping

Wilson's SR-T3 Combo Kit

Buy Now →

The Pharmacokinetic Baseline: What SR-T3 Does Differently

Every practical dosing decision for slow release T3 follows logically from a single pharmacokinetic fact: SR-T3 releases its dose over a 4-8 hour window rather than the roughly 2-hour immediate peak that Cytomel produces. This is not a minor difference in the absorption curve - it is a categorical shift in the serum profile that changes how the thyroid axis, cardiovascular receptors, and adrenergic system respond to each dose.

The mechanism is the HPMC (hydroxypropyl methylcellulose) matrix. When a compounded SR-T3 capsule reaches the stomach, the HPMC polymer swells, forming a gel barrier that meters the dissolution of the embedded liothyronine sodium. The release rate is determined by the viscosity grade of the HPMC selected: lower-viscosity grades (such as HPMC K15M) produce a 4-hour release; higher-viscosity grades (such as HPMC K100M) extend release to approximately 8 hours. A quality compounding formulation specifies the grade; a commodity compounding operation uses whatever bulk HPMC is available.

The downstream effects of the flatter serum curve are what make SR-T3 practically distinct from Cytomel for dosing purposes. First, the area under the curve (AUC) - the total T3 exposure per dose - is comparable to an equivalent immediate-release dose; what changes is the distribution of that exposure over time. Second, the cardiovascular T3 receptors, which are more sensitive to peak concentration than to AUC, see a substantially gentler signal - this is why SR-T3 produces fewer palpitations and less adrenergic activation per microgram of T3 administered. Third, the trough between doses is shallower: with immediate-release T3, the interval between a 2-hour peak and the next dose is predominantly a falling curve; with SR-T3, the 4-8 hour release window narrows the gap between doses considerably, making twice-daily dosing functionally continuous in a way that twice-daily Cytomel is not.

Understanding this baseline is necessary context for every section that follows. Starting-dose conventions, titration tempo, timing decisions, and the interpretation of side effects all shift depending on whether the research subject is using SR-T3 or immediate-release T3. The sustained-release T3 complete guide covers the full pharmacokinetic comparison in table form and explains why this formulation is the research-community standard for the Wilson's protocol and Peat-aligned thyroid research contexts.

Starting Dose: The Research-Community Range

The starting-dose convention for slow release T3 has converged across the research community on a relatively narrow range, though the specific entry point depends on the protocol context and the research subject's baseline health status.

The Wilson's WT3 lineage: 7.5 mcg every 12 hours. The Wilson's Temperature Syndrome protocol - the most structured SR-T3 research framework in use - sets 7.5 mcg every 12 hours as the standard entry point. This maps to the smallest standard SR-T3 capsule strength (7.5 mcg) and establishes a consistent twice-daily dosing rhythm from day one. The rationale for the low entry is not that 7.5 mcg every 12 hours produces significant T3 effect in most research subjects - it typically does not - but that it establishes the dosing schedule, allows the research subject to assess basic tolerability, and provides the first rung of the titration ladder before any meaningful dose escalation begins.

Combination therapy and maintenance protocol: 15-25 mcg once or twice daily. Research subjects adding SR-T3 to an existing T4 (levothyroxine) backbone - the most common clinical application of SR-T3 - often start at a somewhat higher entry dose, because the T4 foundation provides a suppressive context that blunts the T3 response at the low end. A common starting convention for combination therapy is 10-15 mcg of SR-T3 in the morning, with the option to add an evening dose after 2-4 weeks of tolerance assessment. T3 monotherapy (SR-T3 without T4) starts conservatively at 7.5-15 mcg twice daily, given the absence of a T4 buffer.

Body weight and sensitivity adjustments. The research community does not use strict weight-based dosing tables for SR-T3, but body weight and lean mass are informally referenced: a larger research subject carries more T3-receptor-bearing tissue and typically requires higher absolute doses to reach a clinical response. The adjustment is rough - the more important variables are individual sensitivity and starting cofactor status.

When to start lower than the standard Wilson's entry. Several baseline conditions warrant starting below 7.5 mcg every 12 hours, or moving to 7.5 mcg once daily before advancing to twice daily:

• Low cortisol baseline or documented adrenal insufficiency (T3 accelerates cortisol clearance; starting low prevents an acute cortisol-depletion response)
• Severe iron deficiency (ferritin below approximately 30-40 ng/mL correlates with impaired T3 receptor response; high T3 doses in this context may produce symptom burden without benefit)
• Sensitive cardiovascular history or resting heart rate above baseline-normal for the individual
• History of significant anxiety or adrenergic sensitivity

The detailed titration schedule tied to these entry points - including the specific increment sizes, the tempo between steps, and the decision criteria for advancing vs. holding - is covered in the dedicated post in this cluster on starting dose and titration.

The Titration Framework: Step-Wise Dose Escalation

Titration tempo is where the Wilson's cyclic protocol and the longer-duration maintenance approach diverge most sharply, and understanding that divergence helps avoid the most common dosing error in SR-T3 research: titrating too fast on a cyclic protocol or too slowly on a maintenance protocol.

The Wilson's cyclic protocol tempo: 3-5 days between increments. The cyclic T3 approach is designed to push dose relatively aggressively in a structured staircase pattern, using body temperature as the titration endpoint rather than symptom clusters or labs. The standard increment is 7.5 mcg per dose per step - the same as the starting dose - taken every 12 hours. A research subject starting at 7.5 mcg every 12 hours advances to 15 mcg every 12 hours at day 3-5, then to 22.5 mcg every 12 hours at day 6-10, and so on up the titration ladder until the temperature endpoint is achieved or a side-effect ceiling is reached. The 3-5 day minimum between steps is a safety buffer: it allows the cardiovascular and adrenergic response to each new dose level to establish before another increment is added. Moving faster than this increases the risk of dose-stacking - where T3 levels climb before the prior adaptation is complete.

The maintenance protocol tempo: 7-14 days between increments. For research subjects using SR-T3 as a long-duration maintenance intervention rather than a cyclic rT3-clearing protocol, a more conservative titration cadence is appropriate. The longer dwell time at each dose level allows labs (Free T3, TSH) to reach a new equilibrium - TSH suppression in particular has a multi-week pharmacokinetic lag that makes dose assessment at shorter intervals unreliable. Maintenance titration also allows symptom tracking over enough time to distinguish dose-related effects from baseline variability.

The 7.5 mcg increment standard. Both protocol contexts use 7.5 mcg as the standard titration step because it maps to the available capsule strengths and provides the smallest meaningful dose increment that a compounded SR-T3 can practically deliver. Some research subjects find that even 7.5 mcg steps are too large at higher doses (above 45-60 mcg per dose), and switch to smaller increments by opening capsules - a workaround that the bioenergetic research community discusses but that introduces accuracy issues with compounded capsule content.

When to stop titrating. The research-community stopping criteria differ by protocol:

• Cyclic (Wilson's): stop when oral body temperature sustains at 98.6 degrees Fahrenheit or above for three consecutive weeks, OR when side effects (palpitations, significant anxiety, sleep disruption) make further escalation impractical
• Maintenance: stop when Free T3 reaches the upper third of the reference range, symptoms resolve, and the research subject reports stable energy and temperature without adrenergic symptoms

Timing: Morning, Evening, or Split?

The timing of SR-T3 relative to the circadian clock is one of the more actively debated practical questions in the research community, and the debate is genuinely unsettled - the pharmacokinetic and neuroendocrine arguments point in different directions depending on the individual's baseline HPA-axis status, sleep architecture, and response pattern.

The HPA-axis cortisol rhythm interaction. Cortisol follows a well-characterized circadian rhythm: it rises sharply in the early morning hours (the cortisol awakening response, peaking roughly 30-45 minutes after waking) and declines across the day, reaching a nadir in the late evening and early sleep period. Thyroid hormone and cortisol are co-regulators of metabolic rate, and T3 has a documented interaction with the HPA axis at multiple points - T3 amplifies cortisol receptor sensitivity at the cellular level, while cortisol in turn regulates T3 conversion and receptor expression. The practical implication for timing: a morning SR-T3 dose aligns peak T3 exposure (at approximately 4-6 hours post-dose with SR-T3) with the natural late-morning to early-afternoon cortisol decline, rather than stacking T3 on top of the cortisol awakening response. This is the primary pharmacological argument for avoiding a very early morning dose in research subjects with reactive HPA-axis patterns.

Sleep impact. The most consistent concern about evening SR-T3 dosing is sleep disruption. T3 drives metabolic rate, and elevated T3 in the evening - even the gradual elevation of an SR-T3 dose taken in the early evening - can produce enough adrenergic background activity to interfere with sleep onset or sleep architecture. Research subjects who report insomnia on SR-T3 typically identify a later second dose as the contributing factor. This is a recurring enough pattern in the research community that sleep disruption is one of the five troubleshooting spokes in this cluster, covered in the dedicated post on SR-T3 insomnia and sleep timing linked in the troubleshooting section below.

Absorption-window considerations. Because SR-T3 should be taken away from food and interfering substances (detailed in the next section), timing choices interact with the research subject's meal schedule. A first morning dose on an empty stomach on waking, followed by a second afternoon dose before the evening meal, is the most common twice-daily timing convention discussed in the bioenergetic research community. The full analysis of morning vs. evening dosing timing and the case for split dosing - including the specific research-subject presentations where a split 8-hour interval outperforms a strict 12-hour schedule - is covered in dedicated posts in this cluster on morning vs. evening dosing and split dosing in SR-T3 research contexts.

Food and Absorption: The Empty-Stomach Argument

Liothyronine absorption is significantly affected by the gastrointestinal environment at the time of dosing, and SR-T3 is no exception. The pharmacokinetic argument for empty-stomach dosing is well-established for immediate-release T3 and extends logically to the sustained-release form.

The empty-stomach pharmacokinetic case. T3 (liothyronine sodium) is absorbed in the proximal small intestine primarily through active transport mechanisms. Food - particularly fat-containing food - slows gastric emptying and dilutes the drug-to-transporter ratio in the intestinal lumen, reducing the fraction absorbed and extending the time to initial absorption. For immediate-release T3, this effect is clinically documented and consistently cited in clinical pharmacy guidance. For SR-T3, the interaction is more complex: because the release is already extended over 4-8 hours, the gastric-emptying delay from food changes the position of the absorption window relative to the dose rather than merely flattening the already-flat curve. The practical consequence is that the effective timing of the dose relative to any meals that might affect it becomes unpredictable if the research subject does not take SR-T3 consistently on an empty stomach.

Key absorption-interfering substances. The research community maintains a well-defined list of substances that impair T3 (and T4) absorption when taken concurrently:

• Calcium supplements and calcium-containing antacids - bind liothyronine in the GI lumen, reducing absorption
• Iron supplements - high-affinity binding to T3 at intestinal pH; among the most potent absorption inhibitors documented
• Coffee - modest but reproducible reduction in thyroid hormone absorption when taken simultaneously; the practice of waiting at least 30-60 minutes after T3 before coffee is the standard community convention
• Soy products - documented interference via both direct binding and enterohepatic recirculation effects
• High-fiber foods - particularly psyllium husks, bran, and similar bulking agents; can bind thyroid hormone and reduce absorption

The conservative recommendation. The research-community standard for SR-T3 timing around food is: take on an empty stomach, at minimum 60 minutes before eating, or at least 4 hours after a meal. This 60-minute pre-meal and 4-hour post-meal window is derived from T4 absorption studies and applied conservatively to T3 given the active-transport absorption mechanism they share. Research subjects with significant GI motility issues, small intestinal bacterial overgrowth (SIBO), or gastroparesis may have further-impaired absorption independent of food timing. The detailed review of food and absorption research evidence, including the specific magnitude of each interfering substance's effect and the community's practical workarounds, is covered in the dedicated post in this cluster on taking T3 with food or on an empty stomach.

Missed Dose: The Decision Tree

Missing a slow release T3 dose is a common practical occurrence, and the research community has converged on a straightforward decision tree based on half-life pharmacokinetics. The core principle is simple: the goal is dose consistency, not dose recovery, and doubling up to compensate for a missed dose creates the same abrupt peak that SR-T3 is designed to avoid.

Less than 4 hours late. If the missed dose is identified within 4 hours of the scheduled time, take it. The SR-T3 serum curve is still within its normal release window from the prior dose, and taking the late dose now simply shifts the next interval slightly without creating dose stacking or a meaningful gap in T3 coverage.

4 to 12 hours late. This window requires judgment based on the next scheduled dose. If taking the missed dose now would bring it within 4 hours of the next scheduled dose, skip the missed dose and resume the regular schedule at the next dose time. If the gap from the missed dose to the next regular dose is more than 4 hours, taking the missed dose is generally considered acceptable in the research community. The key variable is how far into the trough the research subject has already moved: symptoms of low T3 exposure (fatigue, temperature drop, sluggishness) that appear in this window suggest the missed dose gap is clinically significant.

More than 12 hours late. Skip the missed dose. Resume at the next scheduled time on the regular schedule. At this point, the T3 gap has been substantial, but recovering it with an out-of-schedule dose creates unpredictable serum stacking when the regular schedule resumes.

Never double up. The half-life rationale is this: liothyronine's effective serum half-life is approximately 24 hours, and an SR-T3 dose takes 4-8 hours to fully release. A doubled dose does not simply fill a gap - it creates a loading bolus on top of whatever residual T3 is present from prior doses, producing the kind of peak that SR-T3's formulation was designed to prevent. The specific missed-dose framework with worked examples and the community's approach to managing missed-dose symptom rebounds is covered in the dedicated post in this cluster on missed-dose protocol for SR-T3 research subjects.

Troubleshooting Overview: When Things Don't Go According to Plan

Not every SR-T3 research subject moves through titration without complication. The bioenergetic research community has accumulated enough collective experience with the SR-T3 protocol to map the most common deviation patterns - and to identify which deviations reflect genuine pharmacological problems versus which reflect dosing or timing errors that are straightforward to correct.

The five troubleshooting categories below each have a dedicated spoke in this cluster. The overview here is intended as a triage guide - the one-paragraph summaries point toward the likely mechanism and the spoke link provides the full analysis.

T3 anxiety. Anxiety on SR-T3 manifests differently from the immediate adrenergic spike that Cytomel produces. With SR-T3, anxiety typically has a slower onset, peaking at 3-6 hours post-dose and correlating with the T3 serum peak. The research-community explanation is twofold: cortisol co-activation (T3 amplifies cortisol receptor sensitivity, and if the cortisol baseline is low, T3 can drive an adrenal response that presents as anxiety) and dose-related adrenergic stimulation that exceeds the individual's current tolerance ceiling. The first step in the research community is to rule out cortisol depletion before attributing anxiety to T3 directly. Full mechanism and adjustment protocol: T3 anxiety - mechanism and research-community adjustments.

T3 heart palpitations. Palpitations on SR-T3 are less common than on Cytomel but do occur, particularly at dose escalation steps and in research subjects with pre-existing cardiovascular sensitivity. The pharmacokinetic explanation is that even SR-T3's gradual peak can exceed the individual's current cardiac receptor threshold, especially during the titration phase before cardiac adaptation has occurred. Distinguishing T3-driven palpitations from iron-deficiency-driven palpitations (a common comorbidity in the chronic-illness population) is an important diagnostic step. Full causes and pharmacokinetic analysis: T3 heart palpitations - causes and pharmacokinetics.

T3 morning headache. Morning headache on SR-T3 is one of the more distinctive pattern presentations in the research community because it typically occurs on waking - hours after the last dose - rather than at the T3 peak. The most discussed explanation is a cortisol trough effect: SR-T3, by accelerating cortisol clearance overnight, can leave the early-morning cortisol level lower than the HPA axis can compensate for before waking. The result is a dawn cortisol deficit that presents as headache before the cortisol awakening response is complete. This pattern is distinct from the headache-on-peak that a Cytomel spike produces. Full cortisol-crash pattern and adjustment protocol: T3 morning headache and the cortisol crash pattern.

T3 not working. The non-response pattern - where a research subject is taking SR-T3 at doses that should produce a clinical effect, and consistently does not - is one of the most frustrating outcomes in the community. The research community has identified six explanations that account for the large majority of T3 non-response cases: absorption failure (excipient issues, food interactions, GI pathology), iron deficiency (blocks T3 receptor activation at the nuclear level), selenium deficiency (impairs cofactor-dependent T3 metabolism), cortisol excess or deficiency, estrogen dominance (estrogen upregulates thyroid-binding globulin, reducing free T3), and reverse T3 dominance (rT3 blocking receptor occupancy despite adequate total T3). Full six-explanation framework: Why isn't T3 working - the six explanations.

T3 insomnia. Sleep disruption is the second most commonly reported SR-T3 side effect after cardiovascular symptoms. The timing mechanism is straightforward: evening SR-T3 doses, even at doses that are otherwise well-tolerated, elevate metabolic rate during the window when the circadian sleep drive is increasing, creating a mismatch between the body's metabolic state and the neurological requirements for sleep onset. The solution is typically a timing adjustment rather than a dose reduction. Full sleep-timing analysis and research-subject adjustment protocol: T3 insomnia and slow-release sleep timing.

Lab Monitoring Overview

The research community has converged on a panel of labs that provide meaningful information about SR-T3 protocol status - both for assessing whether the dose is achieving its target effect and for identifying the most common cofactor deficiencies that explain non-response.

The core thyroid panel. Free T3 (FT3) and Free T4 (FT4) are the primary thyroid hormone markers. On SR-T3, Free T3 is expected to rise toward the upper third of the reference range at an effective dose; Free T4 typically declines as TSH suppression reduces thyroid T4 output. TSH suppression is expected and does not, by itself, indicate overdose - the research community consistently distinguishes TSH suppression from thyrotoxicosis, and TSH below the lower limit of the reference range is a predictable and accepted outcome of effective T3 replacement that does not correlate with harm in the absence of clinical overdose symptoms.

Reverse T3. rT3 is the specific test that motivates the Wilson's protocol. The FT3:rT3 ratio (with Free T3 in pg/mL divided by rT3 in ng/dL, target typically above 20) is the research community's preferred functional marker of deiodinase balance. A high rT3 relative to FT3 confirms the dominant diagnosis the Wilson's protocol addresses.

Ferritin. Low ferritin is the single most common cofactor deficiency that impairs T3 response. The research community target is typically above 70-80 ng/mL for functional T3 receptor activation (not merely the deficiency cutoff of 10-12 ng/mL used in conventional medicine). Iron deficiency impairs nuclear T3 receptor function at the cellular level, independent of serum T3 concentration - meaning a research subject can have a normal Free T3 and still have a blunted T3 response if ferritin is low.

Cortisol. A morning cortisol draw (taken at 8 AM, before any T3 dose) provides the most clinically useful snapshot of adrenal reserve. Cortisol below 15-18 mcg/dL at 8 AM in the context of SR-T3 use is a flag for adrenal insufficiency that may be both limiting T3 response and predisposing to the anxiety, headache, and temperature instability patterns described in the troubleshooting section.

Additional cofactors. The research community also monitors selenium (as serum selenium or selenoprotein P), magnesium (intracellular or RBC magnesium rather than serum), and Vitamin D as secondary cofactors that modulate T3 sensitivity and deiodinase function.

The interpretation framework for Free T3 labs - including what constitutes an optimal range vs. merely "in-reference-range" - and the distinction between total T3 and free T3 and when each is informative are covered in dedicated posts in this cluster on Free T3 optimal ranges and total vs. free T3 lab interpretation.

Wilson's WT3 Protocol Context

Many SR-T3 research subjects operate within the Wilson's Temperature Syndrome (WTS) framework - the cyclic T3 protocol developed by Dr. Denis Wilson that is the most structured and widely documented SR-T3 application in the research community. Understanding the Wilson's framework is relevant background even for research subjects using SR-T3 in a maintenance rather than cyclic context, because much of the dosing language, temperature monitoring conventions, and troubleshooting approaches in the bioenergetic community derive from or reference the Wilson's protocol.

The core premise of Wilson's WT3 is that reverse T3 dominance - a state in which the type 3 deiodinase enzyme converts T4 to rT3 preferentially over T3, flooding the thyroid receptor with a biologically inert competitor - can become a self-sustaining pattern that persists long after the original stress trigger has resolved. The mechanism is a feedback loop: rT3 itself downregulates deiodinase activity in a direction that perpetuates its own production. The Wilson's intervention is to administer SR-T3 at doses high enough to suppress TSH (and therefore T4 output, removing the rT3 substrate), while the slow-release formulation maintains receptor occupancy long enough for the deiodinase pattern to reset. The protocol then weans T3 systematically, with the goal of allowing endogenous T4-to-T3 conversion to resume normally once the rT3 dominance pattern has been broken.

The Wilson's approach, the temperature endpoint, and the rationale for using sustained-release rather than immediate-release T3 in this context are covered in depth in the Wilson's T3 protocol guide.

Two distinct phases of the Wilson's protocol generate the most research-community troubleshooting discussion and have their own dedicated posts in this cluster:

The plateau problem - where dose escalation stops producing the expected temperature rise and the protocol appears to stall. The mechanisms the community discusses for Wilson's plateau and the adjustment protocols most commonly applied: Wilson's T3 plateau - when the protocol stops working.

The weaning and tapering phase - where the research subject has reached the temperature endpoint and begins reducing the dose. The weaning phase has its own failure modes - primarily the rebound pattern where temperature drops on dose reduction and requires a slower taper than anticipated. Research-community tapering protocols and rebound management: Wilson's T3 weaning and tapering for research subjects.

The T3→T2 Conversion Bottleneck: When Dose Increases Don't Resolve Symptoms

The Wilson's protocol and SR-T3 maintenance protocols both address the T4→T3 conversion bottleneck: by supplementing T3 directly, research subjects bypass the deiodinase impairment that prevents adequate T3 production from T4. This is the first conversion in a two-step pathway, and the bioenergetic research community has increasingly recognized that there is a second conversion step that the T3-alone protocol does not address.

T3→T2 conversion - the deiodination of triiodothyronine (T3) to 3,5-diiodothyronine (T2) - is catalyzed primarily by the type 1 deiodinase enzyme (DIO1). This is the same enzyme family that is impaired by selenium deficiency, systemic inflammation, elevated cortisol, and the deiodinase dysfunction that motivates T3 supplementation in the first place. A research subject supplementing SR-T3 to correct the T4→T3 bottleneck may be producing adequate serum T3 for nuclear receptor signaling - and still generating insufficient T2 for the mitochondrial mechanism that T2 specifically supports.

The 3,5-T2 mitochondrial mechanism is distinct from T3's genomic action. Where T3 acts through nuclear thyroid hormone receptors (TRalpha and TRbeta) to upregulate mitochondrial enzyme transcription over hours and days, 3,5-T2 acts directly on subunit Va of cytochrome c oxidase - the terminal enzyme of the mitochondrial electron transport chain - to acutely elevate aerobic respiration within minutes. This mechanism does not require nuclear receptor binding and is not replaceable by T3 at any dose. A research subject whose DIO1 function is sufficiently impaired will have both the T4→T3 conversion deficit that SR-T3 corrects and the T3→T2 conversion deficit that T3-only supplementation does not correct.

The practical signature of this second bottleneck is a protocol plateau: the research subject has titrated SR-T3 to a dose that produces adequate or even high Free T3, but metabolic symptoms - persistent low temperature, fatigue, cognitive fog, weight resistance - do not resolve. The dose-response relationship breaks down above a certain point. When this pattern appears, the research community's current framework identifies the T3→T2 deiodinase dysfunction as the most likely explanation. The full mechanistic analysis, the plateau pattern recognition criteria, and the evidence base for the T2 pathway are covered in the existing centerpiece of the T2 cluster: The T3→T2 Conversion Problem: Deiodinase Dysfunction and the Missing Downstream Step.

For research subjects investigating the T3+T2 combination approach - adding 3,5-T2 directly to bypass the T3→T2 conversion bottleneck in the same way that SR-T3 bypasses the T4→T3 bottleneck - the Wilson's T3+T2 Combo is the reference product: T3 and T2 co-formulated at a 1:1 ratio in a sustained-release matrix.

Frequently Asked Questions

What is the starting dose for slow release T3?

The research-community starting dose for slow release T3 in the Wilson's WT3 protocol is 7.5 mcg every 12 hours. For combination therapy (SR-T3 added to a T4 backbone), starting doses of 10-15 mcg once daily in the morning are commonly used, with a second dose added after 2-4 weeks of tolerance assessment. Research subjects with low cortisol baseline, significant iron deficiency, or cardiovascular sensitivity may start at a single 7.5 mcg dose once daily before advancing to twice-daily dosing. The 7.5 mcg entry point reflects the smallest available SR-T3 capsule strength and is designed to establish the dosing rhythm and confirm basic tolerability before any meaningful dose escalation.

Should I take slow release T3 in the morning or evening?

The research community generally favors a morning first dose and an early-to-mid afternoon second dose for twice-daily SR-T3 protocols. This timing aligns the T3 serum peak (at approximately 4-6 hours post-dose with SR-T3) with the post-cortisol-awakening window and avoids the elevated metabolic rate that an evening dose can produce during the sleep-initiation period. Evening dosing is the most commonly cited contributor to SR-T3-related insomnia. That said, some research subjects find that moving the second dose to the late afternoon - rather than early afternoon - improves their cortisol trough pattern without disrupting sleep. The specific timing decision is highly individual and depends on the research subject's HPA-axis pattern, work schedule, and meal timing.

What if I miss a slow release T3 dose?

The missed-dose framework in the research community follows a time-elapsed decision tree. If the missed dose is less than 4 hours late, take it. If it is 4-12 hours late, take it only if the next scheduled dose is more than 4 hours away; otherwise skip it. If more than 12 hours have elapsed, skip the missed dose and resume the regular schedule at the next scheduled time. Do not double the next dose to make up for a missed one: a doubled dose creates a serum stacking effect that produces the kind of T3 peak that SR-T3's sustained-release formulation is specifically designed to prevent.

How long does it take for slow release T3 to work?

Acute metabolic effects - temperature rise, energy shift, and improvement in cold extremity symptoms - often appear within 3-7 days of reaching an effective dose. This does not mean the first titration step produces a response; the effect typically emerges at or above the dose level where T3 exposure is sufficient to overcome the individual's deiodinase set point and receptor threshold. Lab changes - Free T3 rise, TSH suppression, Free T4 decline - take 4-6 weeks to reach a new equilibrium because the thyroid axis has its own pharmacokinetic lag. Symptom resolution for chronic presentations (persistent low temperature, hair loss, weight resistance, cognitive fog) typically requires 8-12 weeks at a stable effective dose, with some research subjects reporting continued improvement over 3-6 months.

Why isn't my slow release T3 working?

Non-response to SR-T3 at doses that should produce an effect is one of the most commonly discussed troubleshooting questions in the bioenergetic research community. The six explanations the community has identified are: absorption failure (food interactions, GI pathology, excipient interference with some research subjects), iron deficiency (ferritin below the functional threshold of approximately 70-80 ng/mL impairs nuclear T3 receptor activation), selenium deficiency (reduces cofactor availability for T3 metabolism), cortisol dysregulation (either excess cortisol suppressing T3 conversion, or insufficient cortisol creating adrenal insufficiency that masks T3 response), estrogen dominance (elevated TBG binding reducing free T3), and reverse T3 dominance (rT3 occupying thyroid receptors despite adequate total T3). The full framework with diagnostic approach for each explanation is covered in the dedicated spoke: Why isn't T3 working - the six explanations.

How do I know I'm at the right dose?

The Wilson's protocol uses oral body temperature as the primary endpoint: temperature sustaining at 98.6 degrees Fahrenheit or above for three consecutive weeks is the target. For maintenance SR-T3 protocols, the research community uses a combination of symptom resolution (energy, temperature, cognitive function, hair quality), Free T3 in the upper third of the reference range, and the absence of adrenergic overdose symptoms (palpitations, anxiety, sleep disruption). A rising Free T3 with persistent symptoms often points toward a cofactor deficiency (iron, selenium, cortisol) rather than insufficient T3 dose. TSH suppression below the reference range is expected and is not itself a stopping criterion in the research community's framework.

Can slow release T3 cause anxiety or heart palpitations?

Yes - both are documented SR-T3 side effects, though they occur less commonly than with immediate-release Cytomel at equivalent doses. Anxiety on SR-T3 most commonly reflects either a cortisol co-activation response (T3 amplifies cortisol sensitivity; if the cortisol baseline is insufficient, the response is perceived as anxiety) or a dose that exceeds the current adrenergic tolerance ceiling. Heart palpitations are typically dose-related and most common at titration steps rather than stable doses. In both cases, the research community's first step is to hold the dose rather than reduce it, observe for 3-5 days, and assess whether the side effect resolves as adaptation occurs. If it persists, dose reduction and slower titration are the standard adjustment. The detailed mechanism and community adjustment protocols are covered in the dedicated spokes for T3 anxiety and T3 heart palpitations.

When should I taper off slow release T3?

In the Wilson's cyclic protocol, the taper begins when oral body temperature has sustained at 98.6 degrees Fahrenheit or above for three consecutive weeks - the endpoint that signals rT3 dominance has been resolved and endogenous T4-to-T3 conversion is potentially ready to resume. The taper mirrors the titration: 7.5 mcg per dose per step, with a minimum of 3-5 days at each step down. In maintenance protocols, the decision to taper is typically made when the underlying pathology has been addressed (for example, when iron repletion, selenium correction, or stress reduction have restored native T4-to-T3 conversion capacity). The weaning phase has its own failure modes, particularly the rebound-temperature-drop pattern that requires slowing the taper tempo. The full weaning and tapering framework is covered in the dedicated cluster spoke: Wilson's T3 weaning and tapering for research subjects.

Closing Note

Slow release T3 dosing is not complicated in its fundamentals - start low, titrate in 7.5 mcg steps, monitor temperature and symptoms, address cofactor deficiencies before attributing non-response to insufficient dose - but the details matter considerably, and the research community's hard-won experience with timing, absorption, missed doses, and the specific failure patterns described above represents a genuine body of practical knowledge that sits outside what mainstream thyroid pharmacology has investigated systematically. This guide provides the cluster framework; each spoke linked in the troubleshooting and timing sections goes deeper on the specific pattern it addresses.

For HPLC-verified research-grade SR-T3 in the standard 5-strength range (7.5, 15, 22.5, 45, 90 mcg), formulated in HPMC matrix with no dyes or allergen-class excipients, see the Wilson's SR-T3 Combo Kit and the full catalog. All compounds discussed in this guide are sold strictly for laboratory research and are not approved for human consumption.